The Efficacy of JAK Inhibitor in the Treatment of Juvenile Dermatomyositis

Research on the Efficacy of JAK Inhibitor in the Treatment of Juvenile Dermatomyositis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400087609

Enrollment

Unknown

Registered

2024-07-31

Start date

2022-07-02

Completion date

Unknown

Last updated

2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile dermatomyositis, JDM

Interventions

A:Conventional treatment

B:JAKi Treatment

Eligibility

Sex/Gender

All

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: (1) Age 2-17 years old; (2) Meets the diagnostic criteria for JDM by Bohan/Peter in 1975 (3) No glucocorticoid or immunosuppressive therapy within six months

Exclusion criteria

Exclusion criteria: Severe juvenile dermatomyositis

Design outcomes

Primary

Measure	Time frame
Major clinical response;	—

Secondary

Measure	Time frame
Adverse reactions (liver and kidney damage, leukopenia, tuberculosis, herpes virus infection, etc.);Skin calcification;Interstitial lung disease;Hormone reduction;	—

Countries

China

Contacts

Public ContactCaifeng Li

Beijing Children's Hospital

shipengli6@163.com+86 133 7011 5006

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026